Heparin Market to Grow by USD 3.34 Billion from 2024-2028, Rising Prevalence of Coagulation Disorders Boosts Growth, Report with Market Evolution Powered by AI - Technavio

NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Report on how AI is driving market transformation - The global heparin market size is estimated to grow by USD 3.34 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 7.22% during the forecast period. Increasing prevalence of coagulation disorders is driving market growth, with a trend towards increasing R and D activities and new therapeutic applications of heparin. However, side effects of heparin poses a challenge. Key market players include Aspen Pharmacare Holdings Ltd, B.Braun SE, Baxter International Inc., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Fresenius SE and Co. KGaA, Hebei Changshan Biochemical, Hikma Pharmaceuticals Plc, Laboratorios Farmaceuticos ROVI S A, LEO Pharma AS, Nanjing Kingfriend Biochemical, Nichi Iko Pharmaceutical Co. Ltd., Novartis AG, Pfizer Inc., Sanofi SA, Shanghai Fosun Pharmaceutical Group Co. Ltd., Shenzhen Techdow Pharmaceutical, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Opocrin SpA.

Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF

Market Driver

The Heparin market is experiencing significant growth due to the rising prevalence of venous thromboembolism (VTE), accidents leading to blood clots in veins and arteries, and the increasing patient population with blood clotting disorders such as pulmonary embolism and deep vein thrombosis. Heparin, an injectable anticoagulant, is widely used to prevent and treat these conditions. Both unfractionated heparin, derived from animal sources like porcine mucosa and bovine intestines, and synthetic heparin are popular options. The market is also influenced by trends in chronic diseases like cardiovascular diseases (CVD), cancer, chronic respiratory diseases, diabetes, and obesity. Heparin is used for long-term anticoagulation therapy in atrial fibrillation, heart attacks, stroke, and hemodialysis. However, challenges such as product contamination, counterfeit drugs, fungal infections, and raw material availability, particularly due to diseases like African Swine Fever impacting the pork industry, pose risks. Key players include Bovine and Porcine heparin, Optimvia, and Fondaparinux sodium. Administration methods include subcutaneous injection and intravenous infusion. The geriatric population and those with orthopedic disorders are major consumer groups. The market is expected to continue growing due to the increasing prevalence of noncommunicable diseases (NCDs) and sedentary lifestyles. 

Heparin, discovered in 1961, is a universal anticoagulant used to treat hemostasis and thrombosis. Its scientific observations and research have significantly impacted our understanding of bleeding and thrombotic disorders. Heparin's applications in surgery, interventions, and medicine have revolutionized healthcare. Major advancements include fractionated heparin and low-molecular-weight heparin, expanding thrombosis management options. 

Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution!

Market Challenges

• The Heparin market faces several challenges in addressing various health conditions that involve blood clotting. Venous thromboembolism, caused by blood clots in veins, and accidents leading to arterial thromboembolism are significant concerns. Heparin, an injectable anticoagulant, is used to prevent blood clotting in at-risk patients, including those with blood clotting disorders, chronic diseases like diabetes, and noncommunicable diseases such as cardiovascular diseases and cancer. Heparin is derived from animal sources, specifically porcine mucosa and bovine intestines, making it an animal-derived product. Challenges include potential contamination, fungal infections, and counterfeit drugs. Heparin is used for both subcutaneous administration and intravenous infusion, with indications including deep vein thrombosis, pulmonary embolism, and thrombosis in the geriatric population and those with orthopedic disorders. Raw materials for heparin production, such as porcine and bovine raw materials, face challenges like African Swine Fever and the pork industry's impact. Synthetic heparin is an alternative, but it faces challenges like product contamination and the high cost of production. Heparin is used for long-term anticoagulation therapy in conditions like atrial fibrillation and for preventing complications in patients undergoing hemodialysis. Fondaparinux sodium, an anticoagulant, is an alternative to heparin and is administered subcutaneously. Other challenges include the increasing prevalence of chronic diseases, sedentary lifestyles, and the aging population.
• Heparin is a well-established anticoagulant with a long history of clinical use. Initially used to prevent blood clotting in vitro, it is now primarily employed to treat thrombosis. Despite the emergence of new anticoagulant drugs, heparin remains the preferred choice for acute thrombotic incidents. Its efficacy is undeniable, but the side effects are a concern. The most common adverse effects include bleeding, heparin-induced thrombocytopenia, osteoporosis, skin reactions, eosinophilia, and allergic reactions. Among these, bleeding, heparin-induced thrombocytopenia, and osteoporosis are the most prevalent. Bleeding is the primary risk with heparin therapy, and major bleeding incidents can be life-threatening. Heparin-induced thrombocytopenia is a condition where the platelet count drops due to heparin exposure. Osteoporosis is a bone density loss associated with long-term heparin use. Both these conditions can significantly impact patient health and require careful monitoring during treatment.

Discover how AI is revolutionizing market trends- Get your access now!

Segment Overview

This heparin market report extensively covers market segmentation by

• Product
• Low-molecular-weight Heparin
• Others
• Route Of Administration
• Subcutaneous Injection
• Intravenous Infusion
• Geography
• Europe
• North America
• Asia
• Rest Of World (ROW)
• Type
• Low Molecular Weight Heparin
• Ultra-Low Molecular Weight Heparin
• Unfractionated Heparin
• Application
• Venous Thromboembolism
• Atrial Fibrillation
• Renal Impairment
• Coronary Artery Disease
• Others

1.1 Low-molecular-weight heparin- Low-molecular-weight heparin (LMWH) is a type of anticoagulant medication that inhibits the coagulation mechanism, preventing the formation of blood clots. It works by activating antithrombin III, which in turn inhibits factor Xa and prevents the conversion of prothrombin to thrombin. LMWH is derived from unfractionated heparin through chemical or enzymatic methods, resulting in shorter chains that last longer and act more effectively in the body. The British National Formulary and the National Institute for Health and Care Excellence have approved LMWH for various indications, including deep vein thrombosis prophylaxis and treatment, pulmonary embolism, and ST-elevation myocardial infarction. Some LMWH options include Fragmin (dalteparin), Lovenox (enoxaparin), parnaparin, certoparin, nadroparin, reviparin, and bemiparin. Dalteparin, with a mean molecular weight of approximately 5,000 Da, offers advantages such as improved bioavailability, prolonged antithrombotic activity, and once-daily administration. It is associated with a lower incidence of heparin-induced thrombocytopenia and thrombosis and decreased osteopenia on prolonged administration. Lovenox (enoxaparin) is an antithrombotic drug indicated for the treatment of unstable angina, deep vein thrombosis, and acute ST-segment elevation myocardial infarction. It has a low incidence of adverse effects and requires less frequent dosing and laboratory monitoring. Parnaparin, with a greater efficacy and longer half-life, permits once-daily administration and has a low incidence of hematomas and pain at the injection site. Certoparin, extensively tested in clinical trials, is effective and safe in preventing venous thromboembolism in various medical and surgical settings. Nadroparin, with a greater ratio of anti-factor Xa to anti-factor Ha activity and longer duration of action, is effective in preventing deep vein thrombosis and pulmonary embolism. Reviparin, with a narrow molecular weight distribution profile and high release of the tissue factor pathway inhibitor, is as effective as unfractionated heparin in various prophylactic indications and causes fewer injection-site hematomas. Bemiparin, a new second-generation LMWH product, has the lowest mean molecular weight, longest half-life, and largest anti-factor Xa activity. Its high release of the tissue factor pathway inhibitor further increases its efficacy. The availability and efficacy of these LMWH products contribute to the growth of the LMWH segment in the global heparin market.

Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics

Research Analysis

The Heparin market refers to the global trade of heparin, an injectable anticoagulant used to prevent and treat various blood clotting disorders. Heparin is essential in managing venous thromboembolism (VTE), a condition characterized by the formation of blood clots in veins, which can lead to complications such as deep vein thrombosis and pulmonary embolism. Heparin works by inhibiting the coagulation cascade, preventing blood clots from forming in both veins and arteries. Heparin is used to prevent clots in patients with chronic blood diseases, diabetes, and those at risk due to accidents, surgeries, or the elderly demographic. It is available in both unfractionated and plasma-derived therapies (PDTs), and can be administered subcutaneously or intravenously. Heparin clinical trials are ongoing to explore its potential in managing atrial fibrillation and other conditions. However, the heparin market faces challenges such as supply chain disruptions due to manufacturing process issues, heparin shortages, and research and development for safer and more effective alternatives. Heparin safety concerns include dosage errors, side effects, drug interactions, and risks during pregnancy and cancer treatment. Despite these challenges, the demand for heparin remains high due to its critical role in anticoagulation therapy, with costs being a significant consideration for healthcare systems worldwide.

Market Research Overview

The Heparin market refers to the global trade of heparin, an injectable anticoagulant used to prevent and treat various blood clotting disorders. Heparin is derived from animal sources, primarily from the mucosal tissues of pigs and cattle. It plays a crucial role in preventing venous thromboembolism (VTE), a condition characterized by the formation of blood clots in the veins, which can lead to life-threatening conditions like deep vein thrombosis (DVT), pulmonary embolism (PE), and heart attacks. Heparin is also used to prevent clots in arteries, known as arterial thromboembolism, and is used in long-term anticoagulation therapy for conditions like atrial fibrillation, cancer, and noncommunicable diseases (NCDs) such as cardiovascular diseases (CVD), chronic respiratory diseases, diabetes, and obesity. Heparin is administered through subcutaneous injection or intravenous infusion, and its raw materials include porcine mucosa and bovine intestinal mucosa. However, challenges in the market include product contamination, counterfeit drugs, and the impact of diseases like African Swine Fever on the pork industry. Other alternatives to heparin include synthetic heparin and plasma-derived therapies (PDTs) like Optimvia, fondaparinux sodium, and anti-inflammatory and anti-viral drugs. The patient population at risk includes the geriatric population, those with orthopedic disorders, and those undergoing hemodialysis. Sedentary lifestyles and aging population also contribute to the rising demand for heparin.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

• Product
• Low-molecular-weight Heparin
• Others
• Route Of Administration
• Subcutaneous Injection
• Intravenous Infusion
• Geography
• Europe
• North America
• Asia
• Rest Of World (ROW)
• Type
• Low Molecular Weight Heparin
• Ultra-Low Molecular Weight Heparin
• Unfractionated Heparin
• Application
• Venous Thromboembolism
• Atrial Fibrillation
• Renal Impairment
• Coronary Artery Disease
• Others

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/heparin-market-to-grow-by-usd-3-34-billion-from-2024-2028--rising-prevalence-of-coagulation-disorders-boosts-growth-report-with-market-evolution-powered-by-ai---technavio-302366492.html

SOURCE Technavio